Stocktoria
EXELIXIS, INC. EXEL
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-04-11
EXELIXIS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 37.6% | 27.9% | 9.3% | 12.5% | 20.0% |
| Net margin | 33.7% | 24.0% | 11.4% | 11.3% | 16.1% |
| FCF margin | 37.7% | 31.0% | 16.0% | 20.8% | 24.2% |
| Return on assets | 27.5% | 17.7% | 7.1% | 5.9% | 8.8% |
| Return on equity | 36.2% | 23.2% | 9.2% | 7.3% | 10.5% |
| Current ratio | 3.56 | 3.63 | 3.34 | 4.99 | 5.43 |
| Revenue growth | 7.0% | 18.5% | 13.6% | 12.3% | 45.3% |
Source: SEC EDGAR filings · CIK 0000939767 · as of 2026-01-02. Facts from filings plus Stocktoria's own computed scores — not investment advice.